Global Amyloidosis Treatment Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794901
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Amyloidosis Treatment Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.

Favourable investment and reimbursement facilities in developed economic countries are the factors driving the growth of Amyloidosis Treatment market.
Factors, such as high cost involved in treatment and limited awareness may hinder the growth of the overall market.

Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to improved healthcare infrastructure, favorable government policies, increased investment, and large amyloidosis cohort.

On the basis of treatment, the market is segmented into Stem Cell Transplant, chemotherapy, supportive care, surgery, targeted therapy. Targeted therapy is likely to demonstrate the fastest growth in the global market, followed by stem cell transplant and surgery.

On the basis of End-user, the Amyloidosis Treatment market is divided into hospitals, clinics, research institute, among others.

Regionally North America market is anticipated to dominate the Amyloidosis Treatment market due to the technological advancement in the diagnostic procedures of oral and dental care.

Some of the key players operating in this market include Pfizer, Inc., Ionis Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd., Johnson and Johnson Pvt. Ltd., and Alnylam Pharmaceuticals, Inc.

Key Benefits of the Report:
* Global, Regional, Country, Treatment, and Route of End-user Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Treatment& End-user, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Amyloidosis Treatment providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity End-user, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Treatment Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 AMYLOIDOSIS TREATMENT MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Amyloidosis Treatment Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Amyloidosis Treatment Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Amyloidosis Treatment Market Company Market Share, 2017
3.6 Amyloidosis Treatment Market — Porter\'s Five Forces Analysis
3.7 Amyloidosis Treatment Market — Pestel Analysis

4 AMYLOIDOSIS TREATMENT MARKET TREATMENT OUTLOOK
4.1 Amyloidosis Treatment Market Share by Treatment, 2016 & 2025
4.2 Stem Cell Transplant
4.4 Supportive care
4.5 Targeted therapy
4.6 Chemotherapy

5 AMYLOIDOSIS TREATMENT MARKET END-USER OUTLOOK
5.1 Amyloidosis Treatment Market Share by End-user, 2016 & 2025
5.2 Hospitals
5.3 Clinics
5.4 Research and institute

6 AMYLOIDOSIS TREATMENT MARKET REGIONAL OUTLOOK
6.1 Amyloidosis Treatment Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Amyloidosis Treatment Market, 2014 - 2025
6.2.2 North America Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.2.3 North America Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.2.5.2 U.S. Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.2.6.2 Canada Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.3 Europe
6.3.1 Europe Amyloidosis Treatment Market, 2014 - 2025
6.3.2 Europe Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.3.3 Europe Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.3.5.2 Germany Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.3.6.2 UK Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Amyloidosis Treatment Market, 2014 - 2025
6.4.2 Asia Pacific Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.4.3 Asia Pacific Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.4.5.2 Australia Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Amyloidosis Treatment Market, By Treatment, 2014 -
2025
6.4.6.2 New Zealand Amyloidosis Treatment Market, By End-user, 2014 -2025
6.4.7 China
6.4.7.1 China Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.4.7.2 China Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.4.8 India
6.4.8.1 India Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.4.8.2 India Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.4.9.2 Japan Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.5 South America
6.5.1 South America Amyloidosis Treatment Market, 2014 - 2025
6.5.2 South America Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.5.3 South America Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.5.5.2 Brazil Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.5.6.2 Mexico Amyloidosis Treatment Market, By End-user, 2014 - 2025
6.6 MEA
6.6.1 MEA Amyloidosis Treatment Market, 2014 - 2025
6.6.2 MEA Amyloidosis Treatment Market, By Treatment, 2014 - 2025
6.6.3 MEA Amyloidosis Treatment Market, By End-user, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Pfizer, Inc
7.1.2 Financial performance
7.1.3 Treatment benchmarking
7.1.4 Strategic initiatives
7.2 Ionis Pharmaceuticals, Inc
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Treatment benchmarking
7.2.4 Strategic initiatives
7.3 Takeda Pharmaceutical Company Ltd
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Treatment benchmarking
7.3.4 Strategic initiatives
7.4 Johnson and Johnson Pvt. Ltd
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Treatment benchmarking
7.4.4 Strategic initiatives
7.5 GlaxoSmithKline, Plc
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Treatment benchmarking
7.5.4 Strategic initiatives
7.6 Alnylam Pharmaceuticals, Inc
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Treatment benchmarking
7.6.4 Strategic initiatives
7.7 Celgene Corp
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Treatment benchmarking
7.7.4 Strategic initiatives

End of the report
Disclaimer.

Content are not available

Choose License Type